Articles On Invion (ASX:IVX)
Title | Source | Codes | Date |
---|---|---|---|
Top 10 at 11: McGrath real estate surges on takeover deal
Stockhead’s Top 10 at 11, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percenta... |
Stockhead | IVX | 3 weeks ago |
Closing Bell: Local markets have made just a terrific recovery as iron ore bounces back
Local markets recover early losses to close slightly ahead Material and Financial gains offset IT and Property losses Small Caps led by ADX Energy Aussie share markets have recovered from early losses to close Monday, ever so slightly i... |
Stockhead | IVX | 1 month ago |
Top 10 at 10: Who’s up 120% on a NVIDIA deal?
Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | IVX | 1 month ago |
Top 10 at 10: Copper finds, M&A … and a sinking Lake Resources
Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | IVX | 1 month ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | IVX | 1 month ago |
Invion announces positive results from pre-clinical study of INV043
Invion (ASX:IVX) has announced the findings of a study by the Peter MaCallum Cancer Centre on the effect of its INV043, when combined with an immune checkpoint inhibitor therapy. |
BiotechDispatch | IVX | 1 month ago |
Closing Bell: Real estate, tech, and gold stocks surge as ASX retreats from all-time high
The ASX 200 index has retreated from its all time high levels on Monday after closing -0.15% lower. As a quick reminder, the index touched a record high of 7,769 last Friday. Sentiment fell after the ABS reported a 1.7% fall in Australian b... |
Stockhead | IVX | 1 month ago |
Top 10 at 11: Tony Sage’s European Lithium completes merger for Wolfsberg lithium project
Stockhead’s Top 10 at 11, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percenta... |
Stockhead | IVX | 1 month ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | IVX | 1 month ago |
Closing Bell: Staples go stupid as ASX200 proves it’s no Dow Jones, but it can be average
Local markets end +0.13% higher in quasi-comeback Consumer Staples soar on bumper Coles news, but offset by everyone else Small Caps led by Audeara on the back of a massive manufacturing sale The indignation of Coles has led Consumer... |
Stockhead | IVX | 1 month ago |
Closing Bell: We’ve got a WhiteHawk up as tech takes over ASX200
Local markets end Friday (and the week) ahead circa 0.4pc IT sector booms 1.5pc Small caps led by WhiteHawk The ASX200 has kept its head and ended Friday higher thanks to a boost from local tech stocks. At 4.15pm on Friday February 23... |
Stockhead | IVX | 1 month ago |
Closing Bell: ASX traders happy to take the profit after surprise CPI windfall
The ASX benchmark has ended Wednesday higher after positive inflation data 7 of 11 sectors in the green, IT ahead by circa +2pc Small caps led by Euro Manganese The local market has trimmed the CPI fat of this morning’s gains, after the... |
Stockhead | IVX | 4 months ago |
In Case You Missed It: UAE agricultural deliveries and some Swedish lithium
Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today. ICYMI Leader... |
Stockhead | IVX | 4 months ago |
Closing Bell: The local bourse giveth and the local bourse wrencheth away and calleth the cops
The ASX benchmark has ended Thursday in a circa -0.8% hole Energy Sector, down -1.4% leads losses Small caps led by RWD The Australian sharemarket has been trimming gains from the open on Thursday, steadily digging a hole in the red as... |
Stockhead | IVX | 5 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | IVX | 5 months ago |
Closing Bell: Australian stocks go higher, for longer on bets The Fed won’t have to
The ASX has ended Wednesday jumping almost 100 points. Huge effort, everyone Energy Sector misses out on all the positive vibes Small caps led by Findi and Firebrick Pharma The Australian sharemarket is in fine fettle on this Wednesday... |
Stockhead | IVX | 5 months ago |
Closing Bell: Even the Aussie dollar appreciates a good lead as dynamic surge makes local IT the it sector for a day
ASX200 closes 0.9pc higher Property stocks and IT sector enjoy huge day Small caps led by DCL The Australian sharemarket has lifted strongly on Day Two of Trading in November, the Best Month for Trading Ever. Local investors got stuck r... |
Stockhead | IVX | 5 months ago |
Closing Bell: A little victory for local markets as ASX gains and China has a weekend to get serious about winning
Benchmark ASX index ends +0.21%, but down -2.2% this week Consumer stocks offset Tech losses Small caps led by Webcentral The benchmark has ended another tortuous week of trade with a little Friday victory. Down -2.2% for the week, all... |
Stockhead | IVX | 5 months ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | IVX | 6 months ago |
In Case You Missed It: It’s wall to wall lithium for the W
Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today. ICYMI Leader B... |
Stockhead | IVX | 6 months ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | IVX | 6 months ago |
ASX Health Stocks: Starpharma full steam ahead on VIRALEZE study, Dimerix to use QYTOVRA as brand name
Dimerix’s drug granted QYTOVRA as brand name by US FDA Starpharma completes recruitment for VIRALEZE study in UK Invion adds South Korea to list of exclusive territories for Photosoft FDA says QYTOVRA can be used as DMX-200 brand name... |
Stockhead | IVX | 6 months ago |
ASX cancer stocks guide: Here’s everything you need to know
According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W... |
Stockhead | IVX | 7 months ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | IVX | 7 months ago |
Top 10 at 11: This morning’s early gains are brought to you by lithium, nickel and… almonds.
Stockhead’s Top 10 at shortly-before-11-ish, published shortly after I’ve located my reading glasses and wiped the bacon grease off my fingers at the start of each trading day. It highlights the best (and sometimes worst) performing ASX sto... |
Stockhead | IVX | 7 months ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | IVX | 7 months ago |
Closing Bell: Range-bound benchmark ends washboard flat, cheapened us all during August
ASX 200 closes about 0.06% in the green (so, really, we ended in the chartreuse) down -1.2 in August Telco and IT Sectors offset Staples and Energy losses Small cap winners include 29M, CDX and HLA Volatility, uncertainty and indecisio... |
Stockhead | IVX | 7 months ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | IVX | 7 months ago |
Closing Bell: ASX200 makes it a hat-trick after Tech Sector triumph
ASX 200 benchmark rises almost 0.6% Tech Sector recovers Wednesday’s losses, after Nasdaq positivity Miners lead small cap gains, ERW, RDN, AZS winning at home in Andover South The Australian share market was up and about early on Thur... |
Stockhead | IVX | 7 months ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | IVX | 8 months ago |
CLOSING BELL: CBA makes bank from rising rates, then issues a warning about mortgage arrears
Local markets have pedalled furiously since lunch to bring the benchmark to +0.35%. CBA posts record $10.2 billion profit off the back of ever-increasing interest rates. Small capper Perpetual stuns with a 50% spike after buying up land in... |
Stockhead | IVX | 8 months ago |
CLOSING BELL: ASX ends flat, but Azure’s inability to stop finding lithium is helping its neighbours grow
ASX benchmark finishes the flat, after struggling to find traction since mid-morning Health Care romped home to win Best Sector today, up more than 0.4% Errawarra’s nearology has continued to pay off, adding around 50% more today. Whil... |
Stockhead | IVX | 8 months ago |
CLOSING BELL: Lithium Australia’s MinRes deal was a bright shining light on an otherwise dreary day.
ASX sleepwalks to an underwhelming -0.3% loss for the day. Real Estate the ‘highlight’, on a paltry +0.5% Lithium Australia’s tech-for-facilities deal with MinRes saw it climb past +80% for the session. It’s been a weak and sorry day o... |
Stockhead | IVX | 8 months ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | IVX | 8 months ago |
Closing Bell: ASX finishes in the green, Real Estate leads the charge
The ASX 200 finishes up 1.56% The ASX XEC rises 1.52% All 11 sectors were higher lead by Real Estate The ASX 200 managed a decent 1.56% lift today, and the ASX XEC was also in the green, up 1.52%. All of 11 sectors were higher, led b... |
Stockhead | IVX | 9 months ago |
CLOSING BELL: Another red day on the ASX as Fed eyes ‘mild recession’ and big miners dip
S&P/ASX 200 closes well in the red today: -1.24% after US stocks dipped on the back of Fed hawkishness Sectors-wise, IT was the only group finishing vaguely in the green, with Materials Discretionary and Financials stocks largely hamm... |
Stockhead | IVX | 9 months ago |
CLOSING BELL: ASX falters with no US market to copy today
S&P/ASX 200 closes in the red today: -0.35%, as US stock markets enjoy a July 4 chilli dog, or something Sectors-wise, Telcos are ringing in the gainz… annnd that’s about it. Okay, Utilities are going alright Standout stocks: Krakatoa... |
Stockhead | IVX | 9 months ago |
ASX June Winners: Who rode this lithium junior to seven-bagger status in June?
The S&P ASX 200 was up 1.76% in June, with large caps performing the best and small caps lagging blue chips The S&P/ASX 200 Materials was the best performing sector in June, up 4.8% coming back from April drop An ASX favourite lith... |
Stockhead | IVX | 9 months ago |
Top 10 at 10: Super gold hits, lithium nearology, and a potential niobium discovery
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | IVX | 9 months ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | IVX | 9 months ago |
CLOSING BELL: Health Care has risen like a zombie to help lift market by 0.5%; Goldies climb 1.1%, too
ASX has finished 0.5% ahead, despite Wall Street’s flabby performance on Friday. Health Care has taken a positive 1.8% step towards fixing last week’s -6.1% disaster. Gold 50 has topped the charts after hitting stellar intercepts at its Ar... |
Stockhead | IVX | 10 months ago |
The Ethical Investor: Why Starpharma and these ASX biotechs could stop the next infectious disease outbreak
The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley Throughout history,... |
Stockhead | IVX | 10 months ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | IVX | 10 months ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | IVX | 10 months ago |
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week Earlier this week, Pfizer surprised the market by say... |
Stockhead | IVX | 10 months ago |
Top 10 at 10: Lithium hydroxide plants and a US$3bn ship building deal
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | IVX | 11 months ago |
Closing Bell: Its a win for the ASX, loss for the newly unemployed as Aussie jobless rate rises
S&P/ASX 200 closes up 0.40%, while the emerging companies index rises 0.43% Algerian mining regulator issues a mining permit for Terramin’s Tala Hamza zinc-lead project Retail component of Next DC’s entitlement offer opens and is expec... |
Stockhead | IVX | 11 months ago |
Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?
The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit Medicare, telehealth and mental... |
Stockhead | IVX | 11 months ago |
CLOSING BELL: Welcome to the ASX, where our motto is ‘chin up, mate… it could’ve been worse’
‘More of the same’ since lunchtime saw the benchmark land at -0.25% for the day Health Care coughed up a 1.09% lift while Financials weighed heavily on -0.71% Magnum Mining wins the Small Caps trophy with +44.1% thanks to Mitsubishi deal... |
Stockhead | IVX | 11 months ago |
Top 10 at 10: Who just pencilled in a big offtake deal with Mitsubishi?
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | IVX | 11 months ago |